Last reviewed · How we verify
Nallpen In Plastic Container (NAFCILLIN SODIUM)
Nallpen In Plastic Container (generic name: NAFCILLIN SODIUM) is a Penicillin-class Antibacterial Small molecule drug developed by Pfizer. It is currently FDA-approved (first approved 1965) for Acute bacterial sinusitis, Infection due to Staphylococcus aureus, Infection of bone.
Nallpen In Plastic Container (Nafcillin Sodium) is a penicillin-class antibacterial medication originally developed by Wyeth Ayerst. It is a small molecule modality that has been FDA-approved since 1965 for various bacterial infections, including those caused by Staphylococcus aureus. Nafcillin Sodium is available as a generic medication, with 11 generic manufacturers, and is considered off-patent. Key safety considerations include its short half-life of 0.7 hours and moderate bioavailability of 30%. It is used to treat a range of infections, including acute bacterial sinusitis, osteomyelitis, and sepsis.
At a glance
| Generic name | NAFCILLIN SODIUM |
|---|---|
| Sponsor | Pfizer |
| Drug class | Penicillin-class Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1965 |
Approved indications
- Acute bacterial sinusitis
- Infection due to Staphylococcus aureus
- Infection of bone
- Infection of skin AND/OR subcutaneous tissue
- Osteomyelitis due to Staphylococcus aureus
- Sepsis due to Staphylococcus aureus
- Staphylococcal Prosthetic Heart Valve Endocarditis
- Staphylococcal endocarditis
- Staphylococcal infectious disease
- Staphylococcal meningitis
- Staphylococcal pneumonia
- Staphylococcus Aureus Joint Infection
Common side effects
- Allergic reactions
- Urticaria
- Pruritus
- Angioedema
- Laryngospasm
- Bronchospasm
- Hypotension
- Vascular collapse
- Death
- Nausea
- Vomiting
- Diarrhea
Drug interactions
- CYP3A4 Substrates
- levonorgestrel
- norgestimate
- warfarin
Key clinical trials
- Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)? (PHASE1)
- Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia (PHASE4)
- Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
- Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes? (PHASE4)
- DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia (PHASE2)
- Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections (PHASE4)
- Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nallpen In Plastic Container CI brief — competitive landscape report
- Nallpen In Plastic Container updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Nallpen In Plastic Container
What is Nallpen In Plastic Container?
What is Nallpen In Plastic Container used for?
Who makes Nallpen In Plastic Container?
What is the generic name of Nallpen In Plastic Container?
What drug class is Nallpen In Plastic Container in?
When was Nallpen In Plastic Container approved?
What development phase is Nallpen In Plastic Container in?
What are the side effects of Nallpen In Plastic Container?
Related
- Drug class: All Penicillin-class Antibacterial drugs
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Acute bacterial sinusitis
- Indication: Drugs for Infection due to Staphylococcus aureus
- Indication: Drugs for Infection of bone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing